Uncooperative is good

Aveo Pharmaceuticals Inc. believes its antibodies targeting the ErbB3 receptor could reduce the incidence of treatment resistance seen with other EGFR inhibitors for cancer. Last week's deal with Biogen Idec Inc. will give Aveo the cash to prove its case, and may provide resources to advance the smaller biotech's in-house cancer program.

The epidermal growth factor (EGF) receptor 3 (HER3, ErbB3) is not a traditional receptor tyrosine kinase like family members ErbB1 or ErbB2, because

Read the full 747 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers